Long-term outcome of breast cancer patients with pathologic N3a lymph node stage

Grassadonia, Antonino; Vici, Patrizia; Gamucci, Teresa; Moscetti, Luca; Pizzuti, Laura; Mentuccia, Lucia; Iezzi, Laura; Scognamiglio, Maria Teresa; Zilli, Marinella; Giampietro, Jamara; Graziano, Vincenzo; Natoli, Clara; Tinari, Nicola

doi:10.1016/j.breast.2016.12.018

Cited by 15 publications

(14 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies investigating the clinical outcome of breast cancer patients with pathologic N3 are summarized in Table 3 [6,[8][9][10][11][12][13]. More recent, studies have reported more improved outcome 70% to 87% of 5-year OS rates and about 35% to 72% DFS rates which was resulted by more advanced standard treatment.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The prognosis factors among breast cancer patients with extensive axillary lymph node metastasis

Kim

Jung

et al. 2018

Korean J Clin Oncol

View full text Add to dashboard Cite

This study was designed to retrospectively identify prognostic factors of survival among breast cancer patients with 10 or more metastatic lymph nodes (LNs). Methods: The study included 58 patients with 10 or more metastatic LNs who received standard treatment from January 2005 to December 2015. To identify the prognostic factors, we analyzed the difference of disease-free survival (DFS) according to clinicopathologic factors. Results: The 5-year DFS and overall survival rates in all patients were 55% and 69%, respectively. Tumor size, number of metastatic LNs and ratio of metastatic to total LNs were associated with poorer prognosis. DFS was significantly poorer in patients with >15 than ≤15 metastatic LNs (hazard ratio [HR], 4.60; 95% confidence interval [CI], 1.38-15.32) and with LN ratio >0.64 than ≤0.64 (HR, 26.13; 95% CI, 3.16-215.80) A scoring system based on these factors was significantly prognostic of survival outcomes. Conclusion: This study identified factors of survival in breast cancer patients with extensive LN metastasis. Patients with unfavorable factors may require modified management to improve their clinical outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Molecular subtype is concerned the significant prognostic factor in breast cancer. However the results in N3 breast cancer showed the diverse results [10,12,13]. Yu et al [10] reported that molecular subtype was associated with DFS only in univariate analysis not in multivariate analysis.…”

Section: Discussionmentioning

confidence: 99%

The prognosis factors among breast cancer patients with extensive axillary lymph node metastasis

Kim

Jung

et al. 2018

Korean J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…reported that HER2‐positive disease and axillary metastasis were independent predictors of recurrence in patients undergoing neoadjuvant chemotherapy and then achieving a pathologic complete remission at the primary site . It is well established that a shorter DFS is associated with clinico‐pathologic factors such as tumor size of >2 cm, the involvement of lymph nodes and more advanced disease stage . In addition, it can be expected that the DFS may be prolonged in patients who achieved a greater control of the disease after receiving adjuvant chemotherapy based on a previous published study showing that it is dependent on types of treatment modalities for patients with BC .…”

Section: Discussionmentioning

confidence: 99%

“…53 It is well established that a shorter DFS is associated with clinico-pathologic factors such as tumor size of >2 cm, the involvement of lymph nodes and more advanced disease stage. 54 In addition, it can be expected that the DFS may be prolonged in patients who achieved a greater control of the disease after receiving adjuvant chemotherapy based on a previous published study showing that it is dependent on types of treatment modalities for patients with BC. 55 There is also another report showing that the use of adjuvant endocrine therapy is associated with a prolonged DFS in patients with hormone-receptor-positive BC.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of fatty acid binding protein‐4 in the invasive ductal carcinoma of the breast

Cui

Song

Kim

2019

Pathology International

View full text Add to dashboard Cite

We conducted this study to identify clinico‐pathologic and prognostic factors that are associated with fatty acid binding protein‐4 (FABP4) and to discuss its therapeutic potentials in patients with breast cancer (BC). In a total of 75 patients with an established diagnosis of invasive ductal carcinoma of the breast, we performed a retrospective analysis of the medical records and analyzed their immunohistochemical findings. Following evaluation of baseline and clinico‐pathological characteristics such as the age, immunohistochemical expressions of FABP4, TNM stage, tumor grade, lymphatic and perineural invasion, estrogen receptor (ER) and progesterone receptor (PR), disease‐free survival (DFS), overall survival (OS), recurrence and death, we analyzed correlations of the expression of FABP4 with clinico‐pathologic and prognostic factors. Our results showed that tumor grade and recurrence had a significant correlation with the expression of FABP4 (P = 0.002 and 0.049, respectively). Moreover, we also found that the DFS had a significant correlation with the expression of FABP4 (P = 0.049). It can therefore be concluded that the expression of FABP4 might have a prognostic value in patients with BC. But further studies are warranted to establish its potentials as a prognostic indicator.

show abstract

“…While the independent predictive value of PR has been questioned [27][28][29][30][31][32], several studies have reported its role as an independent prognosticator of risk of recurrence [33][34][35][36][37][38].…”

Section: Hormone Receptorsmentioning

confidence: 99%

The evolving role of receptors as predictive biomarkers for metastatic breast cancer

Martínez-Pérez

Turnbull

Dixon

2018

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Introduction:In breast cancer, oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: temporal heterogeneity, together with limited sampling methodologies, hinders receptor status assessment and the constant evolution of the disease invariably leads to resistance to treatment. Areas covered:We summarise genomic abnormalities in ER and HER2, such as mutations, amplifications, translocations and alternative splicing, emerging as novel biomarkers that provide an insight into underlying mechanisms of resistance and hold potential predictive value to inform treatment selection. We also describe how liquid biopsies for sampling of circulating markers and ultrasensitive detection technologies have emerged which complement ongoing efforts for biomarker discovery and analysis. Expert commentary:While evidence suggests that genomic aberrations in ER and HER2 could contribute to meeting the pressing need for better predictive biomarkers, efforts need to be made to standardise assessment methods and better understand the resistance mechanisms these markers denote. Taking advantage of emerging technologies, research in upcoming years should include prospective trials incorporating these predictors into the study design to validate their potential clinical value.

show abstract

Long-term outcome of breast cancer patients with pathologic N3a lymph node stage

Abstract: The results of this study indicate that ypN3a stage, lack of expression of PR, and Ki-67 ≥ 20% negatively affect long-term outcome of patients with pN3a breast cancer.

Cited by 15 publications

References 46 publications

The prognosis factors among breast cancer patients with extensive axillary lymph node metastasis

The prognosis factors among breast cancer patients with extensive axillary lymph node metastasis

Prognostic significance of fatty acid binding protein‐4 in the invasive ductal carcinoma of the breast

The evolving role of receptors as predictive biomarkers for metastatic breast cancer

Contact Info

Product

Resources

About